INP-102 (POD-insulin) is a novel treatment being studied by several investigators supported by NIH funding and Impel for Alzheimer’s disease and other cognitive disorders by treating the metabolic deficiencies in dementia. It is estimated that, in 2015, 5.3 million Americans were living with Alzheimer’s disease, which is 11% of the population of the population over 65 years of age. Given that the population over 65 is projected to increase to 86.7 million by 2050 and that the risk for developing AD increases with age, the number of individuals with AD in 2050 could exceed 10 million if no prevention or treatment is discovered.
INP-102 (POD-insulin) is intranasal insulin delivered using POD technology. Embracing a promising approach to treating dementia, nose-to-brain insulin addresses the metabolic slowdown observed in the brains of dementia patients. This novel approach has demonstrated improvement of cognition over baseline after 4 months use and sustained improvement after this time. There is minimal systemic exposure to insulin after it is delivered to the upper nasal cavity, as reported in clinical studies. Impel is currently engaged in multiple investigator-initiated clinical trials with INP-102 (POD-insulin) and is seeking development and licensing partners to globally commercialize this product.